Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes

Messa, E., Cilloni, D., & Saglio, G. (2010). Iron Chelation Therapy in Myelodysplastic Syndromes. Advances in Hematology, 2010(), 231-238. https://doi.org/10.1155/2010/756289
吳育欣、楊仁宏、沈瑞隆（2004）。Myelodysplastic Syndrome Complicated with Leukemia Cutis-A Case Reprot-。中華皮膚科醫學雜誌，22(3)，248-253。https://doi.org/10.29784/DS.200409.0006
MATSUMATA, T., ITASAKA, H., SHIRABE, K., SHIMADA, M., YANAGA, K., & SUGIMACHI, K. (1994). Strategies for Reducing Blood Transfusions in Hepatic Resection. HPB Surgery, 1994(), 1-7. https://doi.org/10.1155/1994/98027
Yao, C. Y. (2017). A 4-lncRNA Scoring System for Prognostication in Adult Myelodysplastic Syndromes [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU201702922
Winichakoon, P., Tantiworawit, A., Rattanathammethee, T., Hantrakool, S., Adisaksopha, C. C., Rattarittamrong, E., Norasetthada, L., & Charoenkwan, P. (2015). Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia. Anemia, 2015(), 80-86. https://doi.org/10.1155/2015/793025